Join
Live feed
·
PRReleasevia Quantisnow
SAB Biotherapeutics Inc. logo

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

ByQuantisnow·Wall Street's wire, on your screen.
SABS· SAB Biotherapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SABS (SAB Biotherapeutics Inc.) and more on Quantisnow.